Physician profile
Prachi Ranade
NPI 1740480771
$696.18
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $142 · 2021: $73.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $173.52 | 2019-2021 | |
| Melinta Therapeutics, LLC | $139.87 | 2019 | |
| Merck Sharp & Dohme LLC | $137.20 | 2019-2021 | |
| Gilead Sciences, INC. | $62.93 | 2019 | |
| Insmed, INC. | $53.68 | 2019-2020 | |
| Allergan, INC. | $52.77 | 2019-2020 | |
| Smith+Nephew, INC. | $37.97 | 2019-2021 | |
| Theratechnologies INC. | $20.33 | 2019 | |
| Astellas Pharma US INC | $17.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prachi Ranade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.